Legends:
Stock price
0.13
Beta (1.0 Market)
% total return 04/18
Stock
S&P500
YTD
34.01
- -
3Y
-16.78
- -
5Y
- -
- -
Capital Structure
FRC

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
- -
- -
- -
LT Borrowings
282
282
283
LT Finance Leases
102
101
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
49
49
Market Capitalization
3,458
3,682
3,171
Working Capital
FRC

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
401
400
395
Cash, Cash Equivalents & STI
304
301
295
Accounts Receivable, Net
39
39
40
Inventories
39
40
42
Total Current Liabilities
64
67
74
Payables & Accruals
60
67
53
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -
Quarterly Revenue
FRC

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
68
78
75
73
294
2022
68
73
71
71
283
2023
74
80
78
82
315

Company News

  • Here's Why You Should Retain Glaukos (GKOS) Stock for Now

  • Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

  • Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

  • Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS

  • Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

  • Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)

  • Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

  • Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?

  • Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?

  • Here's Why You Should Retain Glaukos (GKOS) Stock for Now

  • Here's Why You Should Retain Glaukos (GKOS) Stock for Now